 Precision BioSciences Inc NASDAQ: DTIL announced additional data from its Phase 12a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19. Data will be presented at the 2021 American Society of Clinical Oncology Meeting. 